




NATIONAL BLOOD AUTHORITY
AUSTRALIA

NATIONAL
BLOOD
AUTHORITY
AUSTRALIA

Brand Style Guide



PART A APPLICATION PART B COLLATERAL

Brand Guidelines

- The master logo & logo elements 01
- Clear space guide & minimum size 02
- The master logo colour-ways 03
- Incorrect use—what not to do 04
- Background graphic 05
- Corporate colour palette 06
- Typefaces to use 07

Application **Part A**



THE MASTER LOGO

The logo is central to the National Blood Authority brand and must be reflected on all communication materials.

There are several versions of the National Blood Authority logo which you will see over the next few pages. They each have their own specific uses and applications.

The Master logo featured is, however, the foundation of the National Blood Authority brand. It should be utilised wherever possible.

LOGO ELEMENTS

The National Blood Authority logo is made up of the elements listed below. Please use these terms when referring to particular elements of the logo:

- 01 The Logotype
- 02 The Blood Drop Graphic

TAGLINE

Not present in the logo, the Tagline is an important, supporting brand element that should be applied to collateral where possible. Ideally it should sit right justified across 1-4 lines of text.

- 03 Tagline



CLEAR SPACE GUIDE

The area around the logo must always be kept clear of text and graphic elements, other than the ones listed in the following brand guidelines. This is to ensure the prominence and effectiveness of the logo on any piece of communication.

A clear space equal to the height to the National Blood Authority Logotype block (X) must be maintained around the logo. No text or graphic element should invade this protected area unless they are shown in this Brand Guidelines Document.

MINIMUM SIZE

For purposes of legibility, the minimum size for all versions of the logo is shown to left. The logo may be scaled as large as required.



Logo_Process



Logo_Mono

THE MASTER COLOUR-WAYS

No colour combinations other than those shown here may be used.

The various versions of the National Blood Authority Logo are to be used in all communications, depending on print, web and screen specifications.

THE MASTER LOGO (Process)

The full colour process version of the National Blood Authority Logo is preferred where possible.

MONO (Greyscale)

The National Blood Authority Logo can be reproduced in one colour using Process Black.

THE REVERSED LOGO

The National Blood Authority Logo can be reversed out of black or a coloured background that provides sufficient contrast—the darker the better.



Logo_Reversed





1.



2.



3.

INCORRECT USE— WHAT NOT TO DO

The incorrect use of the Brand Identity and manipulation of the logo against style guidelines is detrimental to the overall strength of the brand. Great care must be taken to avoid this occurring.

Shown to the left are examples of poor manipulation or use of the logo. These are examples of what NOT to do when it comes to the logo usage and presentation.

1. The logo should never be scaled vertically or horizontally.
2. No colour combinations, other than those stated in the corporate palette, should ever be applied to the logo.
3. The elements within the logo should never be moved/rearranged to a structure alternate to the master logo.
4. The relationship between elements in the logo are not to be adjusted or scaled independently of the whole logo.
5. a) The reversed logo should never sit on a busy image;
b) It can only reverse out of the orange, black or an uncluttered part of the photograph that contrasts with the logo.



4.



5a.



5b.

(a)



(b)



BACKGROUND GRAPHIC

A supporting graphic element of the National Blood Authority brand is a grid made up of light grey dots. This grid can overlay the Blood Drop graphic against a crisp white background (a), or may sit over colour blocks (Red, Grey, Blue, Lime, Orange) where a tinted back version of the reversed Blood Drop graphic may be used (b).

This grid expresses the highly technical nature of the organisation's work, reflecting qualities and themes such as scientific, organised, professional, technical and structured.



PANTONE 186 - Red
 CMYK: C0 M100 Y75 K4
 RGB: R:198 G:12 B:48
 HTML: C60C30



PANTONE - PROCESS BLACK
 CMYK: C:0 M:0 Y:0 K:100
 RGB: R:30 G:30 B:30
 HTML: 1E1E1E



PANTONE COOL GREY 6
 CMYK: C:18 M:11 Y:8 K:23
 RGB: R:173 G:175 B:175
 HTML: ADAFAF




PANTONE COOL GREY 4
 CMYK: C:12 M:7 Y:6 K:17
 RGB: R:188 G:189 B:188
 HTML: BCBDBC



PANTONE 2995 - blue
 CMYK: C:87 M:1 Y:0 K:0
 RGB: R:0 G:169 B:224
 HTML: 00A9E0



PANTONE 376 - LIME
 CMYK: C:53 M:0 Y:96 K:0
 RGB: R:122 G:184 B:0
 HTML: 7AB800



PANTONE 1375 - Orange
 CMYK: C:0 M:45 Y:95 K:0
 RGB: R:255 G:160 B:47
 HTML: FFA02F

CORPORATE COLOUR PALETTE

The National Blood Authority's corporate colour palette consists of two primary colours, Red and Cool Grey. These are supported by three accent colours, the blue, lime and orange. These colours form the corporate colour palette and should be used across the suite of communication materials.

Body Copy must always appear in Process Black in the lighter weight, but may use Red or Grey if a heavier weight is used. Pull-out quotes and larger headings may appear in Red, Grey and Black, as long as they are legible and appropriate.

The full colour process must always be matched to the specific Pantone Colour. The PANTONE MATCHING SYSTEM® is a worldwide printing, publishing and packaging language for the selection, marketing and control of colour.

TitilliumText25L (1 wt) Heading 1 or Title Heading

ABCDEFGHIJKLMNOPQRSTUVWXYZ

abcdefghijklmnopqrstuvwxyz

1234567890

TitilliumText25L (999 wt) Heading 2

ABCDEFGHIJKLMNOPQRSTUVWXYZ

abcdefghijklmnopqrstuvwxyz

1234567890

TitilliumText25L (800 wt) Heading 3

ABCDEFGHIJKLMNOPQRSTUVWXYZ

abcdefghijklmnopqrstuvwxyz

1234567890

TitilliumText25L (250 wt)

Body text

ABCDEFGHIJKLMNOPQRSTUVWXYZ

abcdefghijklmnopqrstuvwxyz

1234567890

TitilliumText25L (400 wt)

Body text (reversed or using lighter colour)

ABCDEFGHIJKLMNOPQRSTUVWXYZ

abcdefghijklmnopqrstuvwxyz

1234567890

TYPEFACES TO USE

Headings

TitilliumText25L (1 or 999 weight)—is the approved typeface for the National Blood Authority headings. Consistent use of this typeface will strengthen and support the overall brand. TitilliumText25L must be used for all print, web and screen communication where possible.

In the case of use in Microsoft® products such as Powerpoint and Word, TitilliumText25L must be converted to a graphic in order to be used, otherwise Arial may be substituted.

Bodytext

TitilliumText25L (250, 400)—is the approved body copy typeface for the National Blood Authority. Consistent use of this typeface will help to build the brand identity. TitilliumText25L must be used for all print, web and screen communication where possible.

LETTERHEAD & WITH COMPLIMENTS SLIP	01
BUSINESS CARD	02
A4 CORPORATE REPORT	03
A1 POSTERS	07
A4 FACTSHEET	09
DL FLYER	11
A5 FLYER	13
POWERPOINT	14
ENTRANCE SIGNAGE	15

Collateral **Part B**




back

front

Letterhead & With Compliments Slip

The images to the left are examples of a Letterhead and With Compliments Slip. These have been reduced to 43% of the actual file size.



Business Card

The image below is an example of a Business Card.
This has been placed at 100% of the actual file size.





front



back



A4 Corporate Report

The images below are examples of A4 Corporate Report Covers and an Internal Spread. These have been placed at 32% of the actual file size.






A4 Corporate Report

The images below are alternate examples of A4 Corporate Report Covers, showing how the imagery can be introduced to the design. These have been placed at 27% of the actual file size.



A4 Corporate Report

The images below are examples of A4 Corporate Report Covers, showing how the secondary colours can be used to create a series of publications. These have been placed at 32% of the actual file size.





A1 Posters

The images below are examples of A1 Posters. These have been placed at 14% of the actual file size.

The crucial role of data in supply of blood to patients, reducing wastage and measuring treatment outcomes

Jo Cameron, Leigh McJames, Peter O'Halloran | National Blood Authority, Canberra, ACT

AIM
The National Blood Authority (NBA) aims to develop and implement national information systems that provide the data necessary to improve the appropriate use of blood and the efficiency of blood inventory management. This is driving better patient outcomes, savings at the hospital level and reduced blood costs.

RESULTS
The NBA has developed and implemented four unique national data systems. Bloodflow provides a data platform and enables the management of all hospital blood including the history of all units, usage and inventory trends over time. Bloodflow currently tracks the flow of all O200 hospital inventory, implementation of Bloodflow across Australia is occurring and is scheduled to conclude in 2025. The current state of Bloodflow is:

State/Territory	Inventory	Usage	Inventory	Usage
NSW	100%	100%	100%	100%
VIC	100%	100%	100%	100%
QLD	100%	100%	100%	100%
SA	100%	100%	100%	100%
WA	100%	100%	100%	100%
NT	100%	100%	100%	100%
ACT	100%	100%	100%	100%
National	100%	100%	100%	100%

CONCLUSION
The implementation of these systems provides a unique national capability to capture, manage and analyse blood product usage and inventory trends. This supports hospital, clinician, and patient care and provides a platform for future system development and data analysis.

www.blood.gov.au

NATIONAL BLOOD AUTHORITY AUSTRALIA

LOREM IA MOLUTAR NETA EUM REPORT

> **Oluta quae vidi bea id expe nempor atusae que adis aliberaes reperi identium num, voluptatur apien**

Ut opta cust et harchit busam quantemquam, eglabore perit que corum et aut devinore sunt occatis sus doluptat et incite laut deland dolende licaste oflice commosm volenis volere mo quam arum consicab sprunt ommod quastep chilluptur, occat aut quandilates peratis relenti resatum quam fugiae ea qui dit dis cum non hiciae dunt.

One nos as et re aut voloes quae elerenda re cupitate res nonsectempos delitem ea dolo omnimolore nupja exerspernam nonet ut ea dolloerest, acero vulopti to quam enhit aut baute cupitas si offfio bere corulateri rem mize volumendo et repudictent inuad labio. Solobremore veram estus.

Eless et hil ipsunittis dolobrentor re nobita nobis doluptatum es audigres nos molorum sa stibosam net offfico teclipteque con ratem noniecu lupitis voloptis et aut adiffi sumendis eum reuoc.

Utopa cust et harchit busam quantemquam, eglabore perit que corum et aut devinore

www.blood.gov.au

A1 Posters

The images below are alternate examples of A1 Posters. These have been placed at 14% of the actual file size.

THE CRUCIAL ROLE OF DATA IN SUPPLY OF BLOOD TO PATIENTS, REDUCING WASTAGE AND MEASURING TREATMENT OUTCOMES

Jo Cameron, Leigh McJames, Peter O'Halloran National Blood Authority, Canberra, ACT

AIM

The National Blood Authority (NBA) aims to develop and implement national information systems that provide the data necessary to improve the appropriate use of blood and the efficiency of blood inventory management. This is driving better patient outcomes, savings at the hospital level and reduced blood costs.

RESULTS

The NBA has developed and implemented four unique national data systems. Bloodlet provides a data platform and reporting management capabilities for hospital level including the history of orders, usage and inventory trends over time. Bloodlet currently tracks the data at 100 hospitals nationally. Implementation of Bloodlet across Australia is ongoing and is scheduled to conclude in 2015. The current state of Bloodlet coverage:

State/Territory	Covering Hospitals	Non-Covering
NSW	100	0
VIC	100	0
QLD	100	0
SA	100	0
WA	100	0
TAS	100	0
NT	100	0
ACT	100	0
National	100	0


CONCLUSION

The implementation of these systems provides a unique national capability to capture meaningful, timely and transparent data on blood product ordering, utilization, use and other trends. This supports hospital, clinician, performance and supply. It measures and improves the performance and better patient outcomes.



CONCLUSION

The implementation of these systems provides a unique national capability to capture meaningful, timely and transparent data on blood product ordering, utilization, use and other trends. This supports hospital, clinician, performance and supply. It measures and improves the performance and better patient outcomes.

www.blood.gov.au


LOREM IA MOLUTAR NETA EUM REPORT

> Oluta quae vidi bea id expe nempor atusae que adis aliberaes repere identium num, voluptatur apien

AIM

The National Blood Authority (NBA) aims to develop and implement national information systems that provide the data necessary to improve the appropriate use of blood and the efficiency of blood inventory management. This is driving better patient outcomes, savings at the hospital level and reduced blood costs.

RESULTS

The NBA has developed and implemented four unique national data systems. Bloodlet provides a data platform and reporting management capabilities for hospital level including the history of orders, usage and inventory trends over time. Bloodlet currently tracks the data at 100 hospitals nationally. Implementation of Bloodlet across Australia is ongoing and is scheduled to conclude in 2015. The current state of Bloodlet coverage:

State/Territory	Covering Hospitals	Non-Covering
NSW	100	0
VIC	100	0
QLD	100	0
SA	100	0
WA	100	0
TAS	100	0
NT	100	0
ACT	100	0
National	100	0

CONCLUSION

The implementation of these systems provides a unique national capability to capture meaningful, timely and transparent data on blood product ordering, utilization, use and other trends. This supports hospital, clinician, performance and supply. It measures and improves the performance and better patient outcomes.



CONCLUSION

The implementation of these systems provides a unique national capability to capture meaningful, timely and transparent data on blood product ordering, utilization, use and other trends. This supports hospital, clinician, performance and supply. It measures and improves the performance and better patient outcomes.

www.blood.gov.au


A4 Factsheet

The images below are examples of A4 Factsheets. These have been placed at 43% of the actual file size.



Supply of plasma derived and recombinant blood products

Date: 16 October 2012

> The National Blood Authority (NBA) has supply contracts with various suppliers of blood and blood related products which provide secure product supply at value for money prices supported by comprehensive service requirements of suppliers.

Most plasma derived blood products used in Australia are manufactured by CSL Limited using plasma collected by the Blood Service. Australia is reliant on imported supply of recombinant Factor VIII and IX and additionally plasma derived Factor XI and XIII, anti-inhibitor coagulant complex concentrates, Protein C and plasma-derived intravenous Rh (D) immunoglobulin. These products are either not manufactured in Australia or, as is the case for IVIg, there may be insufficient plasma collected in Australia to be fully self-sufficient.

Depending on the product and in some cases the location involved, the ordering and distribution of plasma and recombinant products under NBA arrangements may be via the manufacturer, a third party distributor contracted by the manufacturer, or the Australian Red Cross Blood Service as a distributor under contract to the NBA. Participating hospitals can use the NBA's BloodNet system to order products, currently where these are distributed by the Blood Service.

A full list of plasma derived and recombinant blood products available under NBA arrangements as at 1 October 2012 is overleaf. The cost of products supplied under NBA arrangements is cost shared 63% by the Commonwealth and 37% by the relevant State or Territory, and the unit price applying under the national funding arrangements is also shown overleaf.



Making a difference and improving supply

The NBA's contracts require suppliers to meet defined performance standards, to maintain supply security reserves, and to provide appropriate product support information and services. It is important for the supplier companies and the NBA to know if doctors, nurses, other health professionals, laboratory staff and even patients are happy with the level of service they are receiving from suppliers. The NBA aims to ensure excellent service and responsiveness by our suppliers. If you are dissatisfied, we would also like to know about it so that we can respond to your concerns and improve services.

All suppliers are required to maintain an accessible channel for receiving feedback and we encourage the use of these to register concerns in the first instance. For example, you should contact the product supplier in the following circumstances:

- > You are unable to place an order with the supplier 24 x 7 and have it acknowledged.
- > Orders are not received by time you requested, or within 48 hours for routine and 24 hours for urgent orders if no time is requested.
- > The product was not delivered to the correct recipient.
- > You do not receive the quantity and presentation size specified in the order.
- > The product delivered is outside the expiry date.
- > You have difficulty in returning product or having faulty or expired product replaced.
- > You do not receive adequate product support, information and advice.

www.blood.gov.au

If a matter is unable to be resolved you can email your concerns to the NBA at supply.management.plasma@nba.gov.au



The National Blood Authority (NBA) has supply contracts with various suppliers of blood and blood related products which provide secure product supply at value for money prices supported by comprehensive service requirements of suppliers.

Most plasma derived blood products used in Australia are manufactured by CSL Limited using plasma collected by the Blood Service. Australia is reliant on imported supply of recombinant Factor VIII and IX and additionally plasma derived Factor XI and XIII, anti-inhibitor coagulant complex concentrates, Protein C and plasma-derived intravenous Rh (D) immunoglobulin. These products are either not manufactured in Australia or, as is the case for IVIg, there may be insufficient plasma collected in Australia to be fully self-sufficient.

Depending on the product and in some cases the location involved, the ordering and distribution of plasma and recombinant products under NBA arrangements may be via the manufacturer, a third party distributor contracted by the manufacturer, or the Australian Red Cross Blood Service as a distributor under contract to the NBA. Participating hospitals can use the NBA's BloodNet system to order products, currently where these are distributed by the Blood Service.

A full list of plasma derived and recombinant blood products available under NBA arrangements as at 1 October 2012 is overleaf. The cost of products supplied under NBA arrangements is cost shared 63% by the Commonwealth and 37% by the relevant State

- > You are unable to place an order with the supplier 24 x 7 and have it acknowledged.
- > Orders are not received by time you requested, or within 48 hours for routine and 24 hours for urgent orders if no time is requested.
- > The product was not delivered to the correct recipient.
- > You do not receive the quantity and presentation size specified in the order.
- > The product delivered is outside the expiry date.
- > You have difficulty in returning product or having faulty or expired product replaced.
- > You do not receive adequate product support, information and advice.

Making a difference and improving supply

The NBA's contracts require suppliers to meet defined performance standards, to maintain supply security reserves, and to provide appropriate product support information and services. It is important for the supplier companies and the NBA to know if doctors, nurses, other health professionals, laboratory staff and even patients are happy with the level of service they are receiving from suppliers. The NBA aims to ensure excellent service and responsiveness by our suppliers. If you are dissatisfied, we would also like to know about it so that we can respond to your concerns.

All suppliers are required to maintain an accessible channel for receiving feedback and we encourage the use of these to register concerns in the first instance. For example, you should contact the product supplier in the following circumstances:

www.blood.gov.au

If a matter is unable to be resolved you can email your concerns to the NBA at supply.management.plasma@nba.gov.au



lois et modo dolab inctur aulligen danti/accis
num quae dicit ornimus scabard fate nonsoed
quis da vent ut inlignu barm modam fignepipi ca
doloate sitacubate vent quater manne.

A4 Factsheet

The images below are alternate examples of A4 Factsheets. These have been placed at 43% of the actual file size.



Australian supply arrangements for intravenous immunoglobulin

Date: 16 October 2012

The national blood supply arrangements provide funded supply of intravenous immunoglobulin (IVIg) for indications in the Criteria for Use of Intravenous Immunoglobulin in Australia Second Edition (IVIg Criteria Second Edition).

Under supply contracts established and managed by the National Blood Authority (NBA), Australia's IVIg requirements are met through a combination of Australian and imported IVIg. Under current arrangements, for indications under the IVIg Criteria Second Edition, IVIg is supplied and authorised through the Australian Red Cross Blood Service (including through BloodNet). For indications outside this edition, IVIg can be ordered directly from suppliers under the Jurisdictional Direct Order arrangements. The table below outlines the products which are currently supplied.

Second Edition of the Criteria for Use of Intravenous Immunoglobulin in Australia

The IVIg Criteria is based on the philosophy that IVIg is a precious biological product and, as such, its use should be consistent with the available evidence base and should be prescribed for the treatment of patients who

are likely to benefit from IVIg therapy and for whom there are no safe and effective alternative treatments.

Following the same approach as the first edition released in 2007, the second edition supports IVIg therapy that is:

- prescribed at the lowest possible dose, for shortest period of time, at lowest frequency to achieve desired therapeutic goal
- used only when other preferable therapies are unavailable or ineffective
- reviewed regularly for patients and treatment stopped if no demonstrable clinical benefit.

For new patients from 10 August 2012, the IVIg Criteria Second Edition will apply. Patients currently receiving product under the first edition of the IVIg Criteria, who are affected by changes, will have a six month transition period. For them, the second edition will take effect from 11 February 2013.

The IVIg Criteria Second Edition also has a handy Quick Reference Guide (that lists all conditions alphabetically).

Visit www.blood.gov.au to download your copy or to order hard copies.

Funding Arrangements	What indications are funded?	What products are available?	Who pays for the product?	How are products accessed?
National Blood Supply Arrangement	Indications funded under the IVIg Criteria	Intragam P 5% (D) Octagam 5% (I) Octagam 10% (I) Kiovig 10% (I)	Cost shared between the Commonwealth and relevant State or Territory	Ordered from and distributed by the Australia Red Cross Blood Service
Jurisdiction Direct Order Arrangement	For indications that are not funded under any IVIg Criteria	Octagam 5% (I) Octagam 10% (I) Fibrogammin 5% DIF (I) Kiovig 10% (I)	Individual jurisdiction, hospital, patient's medical insurance by special agreement/arrangements, or patient bears full cost.	Ordered from and supplied directly by the commercial supplier. Intragam P cannot be ordered under this arrangement.

Key: % = Product Concentration; D = Domestic Product; I = Imported Product



Australian supply arrangements for intravenous immunoglobulin

Date: 16 October 2012

What are the challenges for the supply of IVIg in Australia?

Demand for IVIg in Australia has grown in the last four years at a rate of around 10-11% per year, well above the general population growth rate. Australian plasma collection growth rate is 5% annually, resulting in an increasing reliance on imported IVIg products with 34% of IVIg forecasted to be imported in 2012-13.

Looking ahead, the challenge for the broader health sector and the NBA, as with all blood products, is to contain demand and cost whilst ensuring that patients who will benefit receive treatment.

In addition, there are initial indications in ongoing international clinical trials that there may be positive outcomes from IVIg treatment for sufferers of Alzheimer's disease, potentially halting or slowing the progression of the condition. Should further research confirm these results, the demand for IVIg will rise sharply around the world and will increase pressure on securing plasma sources, the price of IVIg, and global production capacity.



Figure 2. Cost of IVIg supply under national blood arrangements, 2007-08 to 2011-12 and forecast for 2012-13

What is the review of IVIg Authorisation and Clinical Governance arrangements?

Australian governments have recently commissioned a national review of clinical governance and authorisation for IVIg, which has been undertaken by a consulting firm engaged by the NBA. Many specialist clinicians, nurses, laboratory scientists and other stakeholders have provided input during the consultation phases of this review. Findings from the review to date have pointed to the need for a national data system of IVIg authorisation, supply and use; improved clarity of roles and process for authorisation of IVIg requests under the IVIg Criteria Second Edition; an increased role for specialist transfusion nurses in the local management of IVIg; and programs of work in researching and effectively communicating best clinical practice. The recommendations of the review are expected to be provided to governments for consideration by the end of 2012.



Figure 1. Issues of IVIg products, 2007-08 to 2011-12 and forecast for 2012-13

Recent imported IVIg supply contracts

The NBA tenders and contracts with suppliers to give best value for money for Australian governments and the health sector. New contracts for supply of imported IVIg from 1 January 2012 gave savings of around \$3.4 million in the period to 30 June 2012 alone. However, the growth in demand for IVIg still increased the overall cost of the product supplied in 2011-12.

For more information

Visit www.blood.gov.au to access the following resources:

- IVIg Criteria Second Edition, the Quick Reference Guide, FAQs, and other materials
- detailed annual reports on the supply and use of IVIg in Australia for 2009-10 and 2010-11
- more detailed information on current IVIg supply arrangements in Australia


www.blood.gov.au Address Locked Bag 8430, Canberra ACT 2601 Phone +61 2 6151 5000

front


back

DL Flyer

The images below are examples of DL Flyers.
These have been placed at 58% of the actual file size.



front



back

IVIg Criteria Second Edition now available

> **What's it about?**

The *Criteria for the Clinical use of IVIg in Australia Second Edition* identifies conditions and circumstances for which IVIg is funded by all Australian Governments under the National Blood Arrangements.

The second edition of the Criteria is based on the principles that IVIg therapy is:

- prescribed at the lowest possible dose, for shortest period of time, at lowest frequency to achieve the desired therapeutic goal
- used only when other preferable therapies are unavailable or ineffective
- reviewed regularly for patients and treatment stopped if no demonstrable clinical benefit.

This edition is accompanied by a revised version of the handy Quick Reference Guide that lists all conditions alphabetically.

To access the Criteria or Quick Reference Guide visit www.blood.gov.au to download or order hard copies.





> **How does the second edition affect patients?**

The second edition will apply to new patients from 10 August 2012. Existing patients, who are affected by changes to the IVIg Criteria, will have a six month transition period from 10 August 2012 so a review of their IVIg therapy can be considered.

www.blood.gov.au

DL Flyer

The images below are alternate examples of DL Flyer Covers. These have been placed at 58% of the actual file size.



A5 Flyer

The images below are examples of an A5 Flyer.
These have been placed at 53% of the actual file size.



front



IVIg Criteria
Second Edition
now available

> **What's it about?**

The *Criteria for the Clinical use of IVIg in Australia Second Edition* identifies conditions and circumstances for which IVIg is funded by all Australian Governments under the National Blood Arrangements.

The second edition of the *Criteria* is based on the principles that IVIg therapy is:

- prescribed at the lowest possible dose, for shortest period of time, at lowest frequency to achieve the desired therapeutic goal
- used only when other preferable therapies are unavailable or ineffective
- reviewed regularly for patients and treatment stopped if no demonstrable clinical benefit.

This edition is accompanied by a revised version of the handy Quick Reference Guide that lists all conditions alphabetically.

To access *Criteria* or Quick Reference Guide visit www.blood.gov.au to download or order hard copies.

How does the second edition affect patients?

The second edition will apply to new patients from 10 August 2012. Existing patients, who are affected by changes to the IVIg *Criteria*, will have a six month transition period from 10 August 2012 so a review of their IVIg therapy can be considered.


Ut dignis non conseqno blab ipidest empostiat aute sit, volupis doluptam, andus res voloribusdam ulparit vitaspi ciminulpa porpore hentem reius incidunt, as nimi, untorunt.

Osserib usciataie nectusapis rem evelessin reptatat aute poribus eum aciatius, suntis nectes derspeditas accae. Ur, voloribus dolenda sant volupis dest alidic que volorro odit voluapta tempore ressit pedit, sim explautaqi quis culparchiit fugitas maximin tetur?

Idit vition repuda volo occatistur sum doloribusam, cus nimos ut qui nihit, ipsapic iandam iur aut verum sit eumque.

www.blood.gov.au



back




Title Page

Powerpoint


The images below are examples of page from the Powerpoint template. Arial is used (instead of the corporate font Titilium).



Content Pages



Section Title Page



Secondary Heading/Closing Title page

Entrance Signage

The image below shows how branding elements can be applied to the entrance wall signage. The image below is scaled to 3% of the actual file size.



Locked Bag 8430, Canberra ACT 2601 / phone: +61 2 6151 5000 / fax: +61 2 6151 5300 /email: contact@blood.gov.au

www.blood.gov.au